Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
McKesson
Farmers Insurance
Johnson and Johnson
Daiichi Sankyo
UBS
Deloitte
QuintilesIMS
Baxter

Generated: July 17, 2018

DrugPatentWatch Database Preview

Bendroflumethiazide - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for bendroflumethiazide and what is the scope of bendroflumethiazide patent protection?

Bendroflumethiazide
is the generic ingredient in five branded drugs marketed by Apothecon, King Pharms Llc, Impax Labs, and Mylan, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for bendroflumethiazide.
Summary for bendroflumethiazide
Medical Subject Heading (MeSH) Categories for bendroflumethiazide
Synonyms for bendroflumethiazide
(.+/-.)-Bendroflumethiazide
(+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
(+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide
073B483
1,1-dioxo-3-benzyl-6-(trifluoromethyl)-2H,3H,4H-benzo[e]1,2,4-thiadiazine-7-su lfonamide
2259AH
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide, (+-)-
2H-1,2,4-Benzothiadiazine-7-sulfonamide,3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide
3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1?^{6},2,4-benzothiadiazine-7-sulfonamide
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1$l;{6},2,4-benzothiadiazine-7-sulfonamide
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide #
3-benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide
3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide
3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide
3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide
4-27-00-08041 (Beilstein Handbook Reference)
4CN-1235
6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide
73-48-3
96782-79-5
AB00052315
AB00052315_15
AB00052315_16
AC1L1DEI
AK163131
AKOS024255718
AN-5774
API0001605
Aprinox
Be 724-A
Bendrofluazide
Bendroflumethazide
Bendroflumethiazid
Bendroflumethiazide (JAN/USP/INN)
Bendroflumethiazide [USP:INN:BAN:JAN]
Bendroflumethiazide [USP]
Bendroflumethiazide-d5
Bendroflumethiazide, analytical standard
Bendroflumethiazide, British Pharmacopoeia (BP) Reference Standard
Bendroflumethiazide, European Pharmacopoeia (EP) Reference Standard
Bendroflumethiazide, United States Pharmacopeia (USP) Reference Standard
Bendroflumethiazidum
Bendroflumethiazidum [INN-Latin]
Bendroflumetiazida
Bendroflumetiazida [INN-Spanish]
Bendroflumetiazide
Bendroflumetiazide [DCIT]
bendrofumethiazide
Bentride
Benuron
Benzhydroflumethiazide
benzidroflumetiazide
Benzy-rodiuran
Benzydroflumethiazide
Benzylhydroflumethiazide
Benzylrodiuran
Berkozide
BHFT
BL H368
BPBio1_000978
BRD-A80017228-001-05-9
Bristuric
Bristuron
BRN 0373316
BSPBio_000888
BSPBio_003036
C07758
C15H14F3N3O4S2
CAS-73-48-3
CCG-39302
Centyl
CHEBI:3013
CHEMBL1684
Corzide
CPD000058802
CTK8F7951
D00650
D02PAH
DB00436
DivK1c_000274
DSSTox_CID_2647
DSSTox_GSID_22647
DSSTox_RID_76673
DTXSID5022647
EINECS 200-800-1
EU-0009291
Flumersil
Flumesil
FT 8
FT 81
FT-0662517
GTPL7122
HDWIHXWEUNVBIY-UHFFFAOYSA-N
HE020595
HE306828
HE384271
HMS1570M10
HMS1922E15
HMS2092J16
HMS2097M10
HMS2230G10
HMS3259D17
HMS3370I20
HMS500N16
HS-0095
HSDB 3293
IDI1_000274
Intolex
KBio1_000274
KBio2_001866
KBio2_004434
KBio2_007002
KBio3_002536
KBioGR_001188
KBioSS_001866
Livesan
LS-40431
MCULE-7811865125
MLS000028558
MLS001076062
MLS002548857
MolPort-003-666-443
Naigaril
Nateretin
Naturetin
Naturetin (TN)
NATURETIN-10
Naturetin-2.5
NATURETIN-5
Naturine
NC00664
NCGC00016312-01
NCGC00018194-02
NCGC00018194-03
NCGC00018194-04
NCGC00018194-08
NCGC00089729-02
NCGC00089729-03
Neo-naclex
Neo-rontyl
NeoNaClex
Niagaril
Nikion
NINDS_000274
NSC-758229
NSC758229
Opera_ID_1043
Orsile
Pharmakon1600-01503104
Pluryl
Pluryle
Plusuril
Poliuron
Prestwick_992
Prestwick0_000784
Prestwick1_000784
Prestwick2_000784
Prestwick3_000784
rac Bendroflumethiazide
Rautrax N
Rauzide
Relan .beta.
Relan beta
Repicin
Salural
Salures
SAM002264598
SBI-0051772.P002
SCHEMBL26016
Sinesalin
SMR000058802
Sodiuretic
SPBio_001308
SPBio_002827
Spectrum_001386
SPECTRUM1503104
Spectrum2_001524
Spectrum3_001558
Spectrum4_000774
Spectrum5_001016
SR-01000000103
SR-01000000103-2
ST51014919
Thiazidico
Tox21_110365
Tox21_110365_1
UNM000000601501
Urlea
Z2786051551

US Patents and Regulatory Information for bendroflumethiazide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apothecon NATURETIN-2.5 bendroflumethiazide TABLET;ORAL 012164-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Impax Labs NADOLOL AND BENDROFLUMETHIAZIDE bendroflumethiazide; nadolol TABLET;ORAL 077833-002 Mar 30, 2007 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
King Pharms Llc CORZIDE bendroflumethiazide; nadolol TABLET;ORAL 018647-002 May 25, 1983 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Impax Labs NADOLOL AND BENDROFLUMETHIAZIDE bendroflumethiazide; nadolol TABLET;ORAL 077833-001 Mar 30, 2007 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health
UBS
Chinese Patent Office
Accenture
Deloitte
Mallinckrodt
Cipla
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.